February 23, 2024 /

Overview of WVE-N531 and the FORWARD-53 Clinical Trial with Wave Life Sciences

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy

Wave Life Sciences joined PPMD for a community webinar on February 21, 2024 for an update on the company’s FORWARD-53 study. Wave provided an overview of initial clinical trial results for WVE-N531 in individuals with Duchenne muscular dystrophy who are amenable to exon 53 skipping, as well as an overview of the potentially registrational FORWARD-53 study.

Research & Clinical Trial Webinars,
Webinars

Join Our Mailing List

This field is for validation purposes and should be left unchanged.
BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo